Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphomaopen access
- Authors
- Choi, Soyeon; Lee, Yoo Jin; Choi, Yunsuk; Kim, Misung; Kim, Hyun-Jun; Kim, Ji Eun; Oh, Suk Joong; Chae, Seoung Wan; Cha, Hee Jeong; Jo, Jae-Cheol
- Issue Date
- Sep-2022
- Publisher
- 대한병리학회
- Citation
- Journal of Pathology and Translational Medicine, v.56, no.5, pp.281 - 288
- Indexed
- SCOPUS
KCI
- Journal Title
- Journal of Pathology and Translational Medicine
- Volume
- 56
- Number
- 5
- Start Page
- 281
- End Page
- 288
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186089
- DOI
- 10.4132/jptm.2022.07.26
- ISSN
- 2383-7837
- Abstract
- Background: The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.Methods: We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.Results: A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).Conclusions: Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.